Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Psilocybin Phase 3 results from Compass Pathways (COMP005, COMP360) prompted a range of reactions that combine cautious optimism with lingering questions about efficacy. Researchers focused on the apparent underwhelming change in MADRS symptom scores between active and placebo arms, while also noting safety signals that reduce concern. Several interviewees emphasized that better understanding is needed for what “clinically meaningful” improvement actually means, especially in a patient population with limited TRD options. A recurring theme was the need to look beyond symptom scales like MADRS, since mean score changes can mask wide individual differences in real-life outcomes. Researchers also pointed to the importance of placebo responses, participant demographics, and longer term efficacy and durability, with additional attention on future readouts such as COMP006 for clearer efficacy and durability signals.